Laronidase

證據等級: L5

預測適應症: 10 個

Laronidase: From Mucopolysaccharidosis I to Lysosomal Storage Disease with Skeletal Involvement

One-Sentence Summary

Laronidase is a recombinant human alpha-L-iduronidase enzyme replacement therapy, originally developed for Mucopolysaccharidosis I (MPS I; Hurler / Hurler-Scheie / Scheie syndrome) — though this evidence pack’s structured original_indications field is empty, so that indication is inferred from the pack’s own mechanistic rationale and literature, not confirmed by a regulatory source. TxGNN’s top prediction, lysosomal storage disease with skeletal involvement, is in practice a broader ontology label for the same underlying disease the drug already treats, rather than a genuinely new indication. Evidence support is moderate: 4 publications (no registered clinical trials) at evidence level L2.

Quick Overview

Item	Content
Original Indication	Mucopolysaccharidosis I (Hurler / Hurler-Scheie / Scheie syndrome) — not present in this pack’s `original_indications`/license data; inferred from the evidence pack’s own rationale text
Predicted New Indication	Lysosomal storage disease with skeletal involvement
TxGNN Prediction Score	99.31%
Evidence Level	L2
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information that is available, Laronidase is a recombinant form of human alpha-L-iduronidase, the lysosomal enzyme that is deficient in MPS I. Its efficacy in enzyme-replacement therapy for MPS I has been established through decades of clinical use, and mechanistically this activity extends directly to any condition defined by alpha-L-iduronidase deficiency and resulting glycosaminoglycan (GAG) accumulation in bone and connective tissue.

Importantly, the pack’s own repurposing_rationale for this top-ranked prediction states that “lysosomal storage disease with skeletal involvement” is very likely the same disease as MPS I, simply captured under a broader/different ontology term — the TxGNN candidate surfaced here mainly because the drug’s original indication was not populated in this dataset. In other words, this is best read as evidence confirming an already-known use, not a novel repurposing opportunity. A genuine novel-indication assessment would require re-running this analysis with original_indications correctly populated so that TxGNN candidates are filtered against the true label set.

For transparency: the remaining candidates in this pack (Sanfilippo syndrome, lysosomal disease with hypertrophic cardiomyopathy, syndromic neurometabolic disease with X-linked intellectual disability, eyelids malposition disorder) were all scored L4–L5 with a Hold recommendation. Several show evidence mismatches — e.g., the Sanfilippo syndrome literature returned by the pipeline is in fact MPS I literature, most likely due to keyword overlap on “mucopolysaccharidosis” rather than true topical relevance — and the X-linked and hypertrophic-cardiomyopathy candidates lack a plausible genetic/mechanistic basis. None of these support further action at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23127271	2012	Cohort/Case series	Pediatric Neurology	6.5-year follow-up of enzyme replacement therapy in an attenuated MPS I (Scheie syndrome) case; documented skeletal, cardiac, and ophthalmologic outcomes over long-term treatment
25345091	2014	Review	Pediatric Endocrinology Reviews	Overview of MPS I disease spectrum (Hurler / Hurler-Scheie / Scheie), diagnosis via urine GAG pattern and iduronidase enzyme assay
18758061	2008	In vitro (basic research)	Biological & Pharmaceutical Bulletin	Demonstrated mannose-6-phosphate receptor-mediated uptake of laronidase by MPS I fibroblasts and osteoblasts, with lysosomal processing and substrate cleavage
12196045	2002	Review	BioDrugs	Early development overview of laronidase as recombinant alpha-L-iduronidase ERT for MPS I, including orphan drug designation and Phase I trial data

Denmark Market Information

Laronidase currently has no marketing authorisation registered in Denmark (0 authorisations on file; market status: Not marketed).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. This evidence pack does not contain TFDA/Laegemiddelstyrelsen warning or contraindication data (flagged as a Blocking data gap, DG001), and no drug-drug interaction records were found.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The underlying evidence level (L2, supported by MPS I clinical literature) is reasonably solid, but this “new indication” appears to substantially overlap with Laronidase’s already-known use rather than representing a genuinely novel repurposing candidate. Combined with the missing safety/label data, this should not be treated as a green-light case.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain the approved SmPC/product warnings and contraindications before any safety evaluation (S1) can proceed
Resolve DG002: obtain confirmed mechanism-of-action and original-indication data from DrugBank/regulatory sources to determine whether “lysosomal storage disease with skeletal involvement” is truly a new indication or a relabeling of MPS I
If a genuinely novel indication is the goal, re-run the TxGNN candidate generation with a correctly populated original_indications field so existing-use overlaps are filtered out
Given zero marketing authorisations in Denmark, confirm import/named-patient-use pathway status before any clinical consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.